These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33746867)

  • 1. Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease.
    Palacios N; Hannoun A; Flahive J; Ward D; Goostrey K; Deb A; Smith KM
    Front Neurol; 2021; 12():574529. PubMed ID: 33746867
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats.
    van Kessel SP; Bullock A; van Dijk G; El Aidy S
    mSystems; 2022 Feb; 7(1):e0119121. PubMed ID: 35076270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.
    Lubomski M; Xu X; Holmes AJ; Yang JYH; Sue CM; Davis RL
    J Neurol; 2022 Feb; 269(2):780-795. PubMed ID: 34128115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies.
    Lubomski M; Xu X; Holmes AJ; Muller S; Yang JYH; Davis RL; Sue CM
    Front Aging Neurosci; 2022; 14():875261. PubMed ID: 35656540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Cui C; Han Y; Li H; Yu H; Zhang B; Li G
    Front Cell Infect Microbiol; 2022; 12():887407. PubMed ID: 36034698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
    Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
    J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression.
    Aho VTE; Pereira PAB; Voutilainen S; Paulin L; Pekkonen E; Auvinen P; Scheperjans F
    EBioMedicine; 2019 Jun; 44():691-707. PubMed ID: 31221587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
    Hill-Burns EM; Debelius JW; Morton JT; Wissemann WT; Lewis MR; Wallen ZD; Peddada SD; Factor SA; Molho E; Zabetian CP; Knight R; Payami H
    Mov Disord; 2017 May; 32(5):739-749. PubMed ID: 28195358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
    Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
    Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinson's Disease.
    Cerroni R; Pietrucci D; Teofani A; Chillemi G; Liguori C; Pierantozzi M; Unida V; Selmani S; Mercuri NB; Stefani A
    Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut bacterial deamination of residual levodopa medication for Parkinson's disease.
    van Kessel SP; de Jong HR; Winkel SL; van Leeuwen SS; Nelemans SA; Permentier H; Keshavarzian A; El Aidy S
    BMC Biol; 2020 Oct; 18(1):137. PubMed ID: 33076930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
    Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
    Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered gut microbiota in patients with idiopathic Parkinson's disease: an age-sex matched case-control study.
    Babacan Yildiz G; Kayacan ZC; Karacan I; Sumbul B; Elibol B; Gelisin O; Akgul O
    Acta Neurol Belg; 2023 Jun; 123(3):999-1009. PubMed ID: 36719617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia.
    Chung JW; Burciu RG; Ofori E; Coombes SA; Christou EA; Okun MS; Hess CW; Vaillancourt DE
    Neuroimage Clin; 2018; 19():559-571. PubMed ID: 29984164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventional Influence of the Intestinal Microbiome Through Dietary Intervention and Bowel Cleansing Might Improve Motor Symptoms in Parkinson's Disease.
    Hegelmaier T; Lebbing M; Duscha A; Tomaske L; Tönges L; Holm JB; Bjørn Nielsen H; Gatermann SG; Przuntek H; Haghikia A
    Cells; 2020 Feb; 9(2):. PubMed ID: 32041265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Kano O; Tsuda H; Hayashi A; Arai M
    Parkinsons Dis; 2022; 2022():4216452. PubMed ID: 36081594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Gastrointestinal Microbiome Composition in PD: A Pivotal Role of Covariates.
    Cosma-Grigorov A; Meixner H; Mrochen A; Wirtz S; Winkler J; Marxreiter F
    Front Neurol; 2020; 11():1041. PubMed ID: 33071933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.